Based on DNA variations that affect pharmacokinetics and pharmacodynamics, PGx testing can shed light on how individuals may react to particular drugs. This test may help establish what subsequent drug therapy measures should be followed if a patient is taking many medications or has a history of unsuccessful treatments.
Most drugs are broken down (metabolized) in the body by various enzymes. In some cases, an active drug is made inactive (or less active) through metabolism. In other cases, an inactive (or less active) drug is made more active through metabolism.
The challenge in drug therapy is to make sure that the active form of a drug stays around long enough to do its job. However, some people have variable enzyme action so that they may metabolize the drug too quickly or too slowly or not at all — meaning that the drug may not produce its intended effect or it may remain in a person's system too long and may lead to side effects.
By analyzing the genes that produce the specific drug targets or enzymes that metabolize a medication or are associated with immune response, a healthcare practitioner may decide to raise or lower the dose or even change to a different drug.
Depending on the substance, it may take hours or weeks for it to appear in the blood or urine after consumption. Alcohol is one drug that leaves the body rather quickly. However, it can take weeks for other medicines to be discovered following use. THC, a component of marijuana, is one example.
Includes the most popular PGx content including:
ABCB1, APOE, COMT, CYP2C19, CYP2D6,CYP1A2, CYP2B6, CYP3A4, CYP3A5, DRD2,Factor II, Factor V, MTHFR, OPRM1, SLCO1B1, VKORC1, APOE, CYP2C9, CYP3A4, CYP3A5, CYP1A2, ABCB1, CYP2B6, CYP2C19, SLCO1B1, VKORC1, Factor II,Factor V, MTHFR, CYP2B6, DRD2, CYP1A2, OPRM1, CYP2D6,CYP3A4, COMT, CYP2C19, CYP3A5, CYP2C9, CYP2B6, DRD2, CYP1A2, OPRM1, CYP2D6,CYP3A4, COMT, CYP2C19, CYP3A5, CYP2C9, CYP3A4, CYP1A2, CTP2C19, CYP2D6, + MORE